Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[The immunodeficiency treatment unit].

J P Van Vooren1, C M Farber

  • 1jpvanvoo@ulb.ac.be

Revue Medicale De Bruxelles
|February 15, 2003
PubMed
Summary
This summary is machine-generated.

This unit manages over 300 patients with acquired immunodeficiency, including rare primary immunodeficiencies (PID). Research efforts focus on HIV infection, Kaposi's sarcoma, and adverse reactions to intravenous gammaglobulins.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Gastrointestinal infections in the immunocompromised patient].

Acta endoscopica·2020
Same author

[HIV infection : Reaching a zero risk of transmission].

Revue medicale de Bruxelles·2017
Same author

Isolation unit for multidrug-resistant tuberculosis patients in a low endemic country, a step towards the World Health Organization End TB Strategy.

Epidemiology and infection·2017
Same author

Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study†.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Long-incubation-time gamma interferon release assays in response to purified protein derivative, ESAT-6, and/or CFP-10 for the diagnosis of Mycobacterium tuberculosis infection in children.

Clinical and vaccine immunology : CVI·2013
Same author

Biological response of endothelial cells and its modulation by cytokines: prospects for therapy and bioprocesses.

Cytotechnology·2012
Same journal

[Breast cancer screening : a tool for informed decision making].

Revue medicale de Bruxelles·2018
Same journal

[Breast cancer screening : present situation and prospects].

Revue medicale de Bruxelles·2018
Same journal

[Guidelines in medical imaging : objectives, limits and radiation protection].

Revue medicale de Bruxelles·2018
Same journal

[How to avoid overmedicalization of the elderly patient ?]

Revue medicale de Bruxelles·2018
Same journal

[Ethical, pedagogical, socio-political and anthropological implications of quaternary prevention].

Revue medicale de Bruxelles·2018
Same journal

[New strategies in specific care for benign prostatic hypertrophy in older men].

Revue medicale de Bruxelles·2018
See all related articles

Area of Science:

  • Immunology
  • Infectious Diseases
  • Genetics

Context:

  • Established in 1981, the unit became an independent Reference Centre in 1998.
  • Multidisciplinary team follows over 300 patients regularly.
  • Focus on acquired immunodeficiency and less-publicized primary immunodeficiencies (PID).

Purpose:

  • To provide specialized care for patients with acquired and primary immunodeficiencies.
  • To conduct research into the pathogenesis and treatment of immunodeficiency-related conditions.
  • To investigate genetic factors influencing HIV infection and immune responses.

Summary:

  • The unit cares for over 300 patients with acquired immunodeficiency and approximately 60 with primary immunodeficiencies (PID).
  • Research includes identifying an HIV co-receptor mutation conferring protection against HIV infection.

Related Experiment Videos

  • Studies also cover Kaposi's sarcoma pathogenesis and adverse reactions to intravenous gammaglobulins.

    • Impact:

    • Advances understanding of rare "orphan" diseases like PID, highlighting their severity comparable to AIDS.
    • Contributes to identifying genetic resistance to HIV infection.
    • Improves management of immune-related adverse events and complex immunodeficiencies.